Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | P4HB | P07237 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30873796 | 1.00 | CTSL (0.53) | CTSLCTSSCTSKMAPTMEN1 | |
| SCHEMBL10629655 | 0.85 | MAPT (0.43) | CTSLCTSSCTSKMAPTMEN1 | |
| SCHEMBL27621167 | 0.84 | CTSL (0.53) | CTSLCTSSCTSKMAPTMEN1 | |
| SCHEMBL8022191 | 0.84 | CTSL (0.53) | CTSLCTSSCTSKMAPTMEN1 | |
| SCHEMBL8528011 | 0.84 | CTSL (0.53) | CTSLCTSSCTSKMAPTMEN1 | |
| SCHEMBL5913306 | 0.84 | CTSL (0.53) | CTSLCTSSCTSKMAPTMEN1 | |
| SCHEMBL13660444 | 0.83 | CTSS (0.48) | CTSLCTSSCTSKMEN1KMT2A | |
| SCHEMBL11633908 | 0.82 | TACR1 (0.48) | CTSLCTSSCTSKMAPTMEN1 | |
| SCHEMBL5209782 | 0.82 | SSTR3 (0.53) | CTSLCTSSCTSKMAPTMEN1 | |
| SCHEMBL9371255 | 0.81 | MAPT (0.54) | CTSLCTSSCTSKMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924391-A | Cytosine nucleoside derivative containing amide structure and preparation method and application thereof | 沈阳农业大学 | 2024-04-26 | — | — | CN | disclosed |
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| CN-103402996-B | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD) | NOVARTIS AG | 2015-02-11 | — | — | CN | disclosed |
| CN-103402996-A | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD) | NOVARTIS AG | 2013-11-20 | — | — | CN | disclosed |
| EP-2661433-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Novartis AG (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | disclosed |
| US-4108854-A | Process for preparing substituted glycines | SMITHKLINE CORPORATION (US) | 1978-08-22 | — | — | US | disclosed |
| US-3997584-A | Substituted glycines and intermediates thereof | SMITHKLINE CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
| US-3994954-A | Process for preparing substituted glycines | SMITHKLINE CORPORATION (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | CTSL 1024/4885CTSS 1774/4885CTSK 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.